#AS­CO21: J&J busts out a small up­date for its an­ti­body-TKI com­bo in lung can­cer — whet­ting ap­petites as FDA thinks it over

In a red-hot EGFR-mu­tat­ed non-small cell lung can­cer mar­ket, John­son & John­son thinks it could have a leader in its bis­pe­cif­ic an­ti­body ami­van­tam­ab. But as com­peti­tors crowd in, J&J is look­ing to back up its case for ap­proval, and it’s rolling out just a taste of that da­ta to back its case in rare mu­ta­tions.

A com­bi­na­tion of J&J’s EGFR/MET bis­pe­cif­ic an­ti­body ami­van­tam­ab and small-mol­e­cule TKI drug laz­er­tinib post­ed a me­di­an du­ra­tion of re­sponse of 9.6 months in pa­tients with NSCLC with ex­on 19 dele­tion or L858R mu­ta­tion that hadn’t pre­vi­ous­ly un­der­gone chemo but pre­vi­ous­ly failed on As­traZeneca’s Tagris­so, ac­cord­ing to co­hort da­ta from the Phase I/II CHRYSALIS study set to be pre­sent­ed at AS­CO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER